For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Eisai to Mobilize All of Its 1,400 MRs to Promote Bendamustine from SymBio
November 8, 2010
- FDA Approves Herceptin for Metastatic Stomach Cancer
November 8, 2010
- DSP: Sales Up 42.6% Due to Addition of Sunovion
November 8, 2010
- Byetta Approved as Japan's 2nd GLP-1 Agonist in Japan: Eli Lilly
November 8, 2010
- Roche Applies for Actemra for sJIA in the US, EU
November 8, 2010
- AZ, Daiichi Sankyo to Copromote Esomeprazole in Japan
November 8, 2010
- Samsca Approved for Excess Water Retention: Otsuka
November 8, 2010
- PhRMA Welcomes Korosho's Vaccine Committee Report
November 8, 2010
- AZ Aims to Add Sales of ¥100 Bil. by 2015
November 8, 2010
- Invega for Schizophrenia, OneDuro Patch for Cancer Pain Approved: Janssen
November 8, 2010
- Shionogi to Jointly Develop New Cephem Antibiotics with GSK
November 8, 2010
- Daiichi Sankyo Wins Levofloxacin Patent Lawsuit in the US
November 8, 2010
- Non-Steroidal Eye Drop Nevanac Approved: Alcon
November 8, 2010
- Group of Clinicians Protests against Asahi Shimbun for Reports on Vaccine Clinical Trial
November 8, 2010
- Shionogi, Sawai Settle Patent Infringement Lawsuit for Flomox
November 8, 2010
- Anti-Histaminic Xyzal Approved: GSK
November 8, 2010
- Chugai Develops New Technology to Produce Reusable MAb
November 8, 2010
- Generics May Save ¥200 Mil. Per Month: Kyokaikenpo
November 8, 2010
- Revolade Approved for ITP: GSK
November 8, 2010
- Chugai Presents Data on Eldecalcitol from Japanese Patients
November 8, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…